<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45290">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01995526</url>
  </required_header>
  <id_info>
    <org_study_id>14682</org_study_id>
    <secondary_id>I2R-JE-BIDK</secondary_id>
    <nct_id>NCT01995526</nct_id>
  </id_info>
  <brief_title>A Study of Insulin Peglispro in Healthy Male Japanese Participants</brief_title>
  <official_title>A Single Dose Study to Evaluate the Pharmacokinetics and Glucodynamics of Insulin Peglispro (LY2605541) in Healthy Male Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <authority>Japan: Institutional Review Board</authority>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate how the body processes the study drug known as
      insulin peglispro and how the study drug affects blood sugar in healthy male Japanese
      participants. This study will also evaluate safety of the study drug. The study will last up
      to 46 days for each participant, not including screening.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Pharmacokinetics: Maximum Concentration (Cmax) of Insulin Peglispro</measure>
    <time_frame>Day 1:  Predose up to 192 hours postdose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics:  Area Under the Concentration Curve (AUC) of Insulin Peglispro</measure>
    <time_frame>Day 1:  Predose up to 192 hours postdose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucodynamics: Maximum Glucose Infusion Rate (Rmax)</measure>
    <time_frame>Day1: Predose up to 36 hours post dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucodynamics: Total Amount of Glucose Infused (Gtot)</measure>
    <time_frame>Day1: Predose up to 36 hours post dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Insulin Peglispro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin peglispro is given subcutaneously once.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Peglispro</intervention_name>
    <description>Administered subcutaneously</description>
    <arm_group_label>Insulin Peglispro</arm_group_label>
    <other_name>LY2605541</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants are overtly healthy male Japanese.

          -  Participants have Body Mass Index (BMI) between 18.5 and 25.0 kilogram per square
             meter (kg/m^2), inclusive.

        Exclusion Criteria:

          -  Participants have known allergies to insulin peglispro, related compounds.

          -  Participants have a fasting venous blood glucose &gt;108 milligram per deciliter (mg/dL)
             (&gt;6 millimole per liter [mmol/L]).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 15, 2014</lastchanged_date>
  <firstreceived_date>November 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
